FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893399598> ?p ?o ?g. }

• W2893399598 endingPage "6338" @default.
• W2893399598 startingPage "6333" @default.
• W2893399598 abstract "Nab-paclitaxel is produced by the combination of paclitaxel particles with human serum albumin. Encouraging efficacy has been observed with nab-paclitaxel-based chemotherapy in a variety of solid tumors. The aim of the study reported here was to evaluate the efficacy and safety of weekly nab-paclitaxel plus cisplatin with concurrent intensity-modulated radiotherapy in patients with locally advanced esophageal cancer.Seventeen patients with esophageal cancer were enrolled between July 2014 and December 2015.The treatment included radical radiotherapy (95% planning target volume 60Gy/30f) and concurrent chemotherapy comprising nab-paclitaxel 60mg/m2/week plus cisplatin 25mg/m2/week, administered on days 1, 8, 15, and 22 of each 28-day cycle. The end point of this study included objective response rate (ORR), local-recurrence free survival (LRFS), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS).All the patients enrolled in the trial had squamous cell carcinoma. The median follow-up duration was 20.47 months. The ORR was 88.2%. LRFS, DMFS, PFS and OS at 3 years were 61%, 40%, 17% and 35%, respectively. The trial regimen was well tolerated, with grade 3-4 myelosupression, grade 3 radioactive esophagitis, and grade 3 radiation pneumonitis rates of 17.6%, 17.6%, and 11.8%, respectively.Weekly nab-paclitaxel plus cisplatin with concurrent intensity-modulated radiotherapy is an effective and well-tolerated treatment option for inoperable, locally advanced squamous cancer of esophageal." @default.
• W2893399598 created "2018-10-05" @default.
• W2893399598 creator A5004354888 @default.
• W2893399598 creator A5025277732 @default.
• W2893399598 creator A5036013509 @default.
• W2893399598 creator A5057417537 @default.
• W2893399598 creator A5060654448 @default.
• W2893399598 creator A5064729480 @default.
• W2893399598 creator A5090340361 @default.
• W2893399598 creator A5091584882 @default.
• W2893399598 date "2018-09-01" @default.
• W2893399598 modified "2023-09-26" @default.
• W2893399598 title "Efficacy and safety of weekly nab-paclitaxel plus cisplatin with concurrent intensity-modulated radiotherapy in patients with inoperable, locally advanced esophageal cancer: a pilot trial" @default.
• W2893399598 cites W1968626722 @default.
• W2893399598 cites W1972057525 @default.
• W2893399598 cites W2019607817 @default.
• W2893399598 cites W2027232973 @default.
• W2893399598 cites W2040486812 @default.
• W2893399598 cites W2117223681 @default.
• W2893399598 cites W2122166737 @default.
• W2893399598 cites W2127356591 @default.
• W2893399598 cites W2143000178 @default.
• W2893399598 cites W2144263975 @default.
• W2893399598 cites W2144536924 @default.
• W2893399598 cites W2149564448 @default.
• W2893399598 cites W2151969982 @default.
• W2893399598 cites W2153017356 @default.
• W2893399598 cites W2164067249 @default.
• W2893399598 cites W2165480504 @default.
• W2893399598 cites W2178792932 @default.
• W2893399598 cites W2264815585 @default.
• W2893399598 cites W2281594064 @default.
• W2893399598 cites W2406534763 @default.
• W2893399598 cites W2416425543 @default.
• W2893399598 cites W4236554935 @default.
• W2893399598 doi "https://doi.org/10.2147/ott.s168275" @default.
• W2893399598 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6167982" @default.
• W2893399598 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30319273" @default.
• W2893399598 hasPublicationYear "2018" @default.
• W2893399598 type Work @default.
• W2893399598 sameAs 2893399598 @default.
• W2893399598 citedByCount "8" @default.
• W2893399598 countsByYear W28933995982020 @default.
• W2893399598 countsByYear W28933995982021 @default.
• W2893399598 countsByYear W28933995982023 @default.
• W2893399598 crossrefType "journal-article" @default.
• W2893399598 hasAuthorship W2893399598A5004354888 @default.
• W2893399598 hasAuthorship W2893399598A5025277732 @default.
• W2893399598 hasAuthorship W2893399598A5036013509 @default.
• W2893399598 hasAuthorship W2893399598A5057417537 @default.
• W2893399598 hasAuthorship W2893399598A5060654448 @default.
• W2893399598 hasAuthorship W2893399598A5064729480 @default.
• W2893399598 hasAuthorship W2893399598A5090340361 @default.
• W2893399598 hasAuthorship W2893399598A5091584882 @default.
• W2893399598 hasBestOaLocation W28933995981 @default.
• W2893399598 hasConcept C121608353 @default.
• W2893399598 hasConcept C126322002 @default.
• W2893399598 hasConcept C126894567 @default.
• W2893399598 hasConcept C143998085 @default.
• W2893399598 hasConcept C2776694085 @default.
• W2893399598 hasConcept C2777292972 @default.
• W2893399598 hasConcept C2778239845 @default.
• W2893399598 hasConcept C2779134260 @default.
• W2893399598 hasConcept C2779742542 @default.
• W2893399598 hasConcept C2779920096 @default.
• W2893399598 hasConcept C2781413609 @default.
• W2893399598 hasConcept C43270747 @default.
• W2893399598 hasConcept C509974204 @default.
• W2893399598 hasConcept C71924100 @default.
• W2893399598 hasConceptScore W2893399598C121608353 @default.
• W2893399598 hasConceptScore W2893399598C126322002 @default.
• W2893399598 hasConceptScore W2893399598C126894567 @default.
• W2893399598 hasConceptScore W2893399598C143998085 @default.
• W2893399598 hasConceptScore W2893399598C2776694085 @default.
• W2893399598 hasConceptScore W2893399598C2777292972 @default.
• W2893399598 hasConceptScore W2893399598C2778239845 @default.
• W2893399598 hasConceptScore W2893399598C2779134260 @default.
• W2893399598 hasConceptScore W2893399598C2779742542 @default.
• W2893399598 hasConceptScore W2893399598C2779920096 @default.
• W2893399598 hasConceptScore W2893399598C2781413609 @default.
• W2893399598 hasConceptScore W2893399598C43270747 @default.
• W2893399598 hasConceptScore W2893399598C509974204 @default.
• W2893399598 hasConceptScore W2893399598C71924100 @default.
• W2893399598 hasLocation W28933995981 @default.
• W2893399598 hasLocation W28933995982 @default.
• W2893399598 hasLocation W28933995983 @default.
• W2893399598 hasLocation W28933995984 @default.
• W2893399598 hasLocation W28933995985 @default.
• W2893399598 hasOpenAccess W2893399598 @default.
• W2893399598 hasPrimaryLocation W28933995981 @default.
• W2893399598 hasRelatedWork W2055272681 @default.
• W2893399598 hasRelatedWork W2100029565 @default.
• W2893399598 hasRelatedWork W2187491254 @default.
• W2893399598 hasRelatedWork W2351552234 @default.
• W2893399598 hasRelatedWork W2362015479 @default.
• W2893399598 hasRelatedWork W2363247516 @default.
• W2893399598 hasRelatedWork W2370387906 @default.
• W2893399598 hasRelatedWork W2522899364 @default.

• next